Soley Therapeutics Announces Breakthrough Research Demonstrating How Cellular Stress Responses Reveal Drug Mechanisms, Enabling Entirely New and Accelerated Methods for Drug Discovery
Soley Therapeutics today announced the publication of a peer-reviewed study in Scientific Reports describing a new approach to understanding how living cells react to drug molecules, inverting traditional target-based drug discovery methods. The study shows that dynamic live-cell stress responses to drugs over time encode mechanistic information about a cell’s trajectory to survive, adapt, or die – information that is largely missed by traditional snapshot-based assays. This work establishes the scientific foundation for Soley’s platform, which enables a novel, proprietary live-cell approach to drug discovery based on how cells sense and respond to stress.
Soley Therapeutics Announces $200 Million Series C Financing to Propel Lead Oncology Programs into the Clinic and Scale Its Cell Stress Sensing Platform
Soley Therapeutics (“Soley”) today announced a $200 million Series C financing to advance its proprietary cell stress sensing platform and pipeline of novel therapeutics into the clinic. Proceeds will support IND-enabling work and clinical trials for two first-in-class internally discovered and developed oncology assets, in addition to advancement of the non-oncology stress-reducing drug candidates for neurodegenerative disorders and metabolic diseases, and continued platform scale-up.
